Takeda Oncology
Annarita Egidi serves as the Head of Oncology Business Unit for Europe and Canada at Takeda Oncology since August 2023. With extensive experience at Takeda Italia from October 2013 to July 2023, Annarita held various leadership roles including General Manager, Oncology Country Head, and Oncology Business Unit Director. Prior to joining Takeda, Annarita worked at Pfizer from April 2004 to October 2013 as Pricing and Reimbursement Strategy Manager and Associate Director for Global Pricing & Reimbursement. Annarita began her career as a Pharmaceutical Rep at Recordati and later as a Product Manager at GlaxoSmithKline. Annarita holds a GMP in Economics from ESCP Business School and a Laurea in Pharmaceutical Chemistry from Sapienza Università di Roma.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.